O-glycoside Patents (Class 514/25)
  • Patent number: 10695319
    Abstract: Provided are compounds generated by conjugation of triptolide with glucose to form glucose-triptolide conjugates, provides compounds with effective anti-proliferative activity and improved tolerability as compared to naturally occurring triptolide compounds.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 30, 2020
    Assignees: The Johns Hopkins University, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
    Inventors: Jun Liu, Qingli He, Martin G. Pomper, Il Minn, Biao Yu, Qiaoling Wang
  • Patent number: 10696662
    Abstract: The present invention is directed to 5-fluoro-C-(aryl or hetercyclyl)-glycoside derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 30, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Gee-Hong Kuo, Micheal Gaul
  • Patent number: 10682346
    Abstract: The present invention provides methods of use of hexokinase 2 (HK2)/mitochondria-detaching compounds, including jasmonate derivatives and piperazine derivatives and pharmaceutical compositions including such compounds for inducing immune responses in a subject, including potentiating the immune response to hyperproliferative disorders such as cancer and potentiating the immune response to infectious diseases.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 16, 2020
    Assignee: VIDAC PHARMA LTD.
    Inventors: Vered Behar, Oren Menahem Becker, Reut Yosef Hamo, Eyal Dor-On
  • Patent number: 10683525
    Abstract: The present invention relates to a method for producing 2-O-glyceryl-?-D-glucopyranoside (?GG; FIG. 1) from a glucosyl donor and a glucosyl acceptor comprising the steps: providing a sucrose phosphorylase (EC 2.4.1.7), incubating said sucrose phosphorylase with a mixture comprising a glucosyl donor and glycerol as glucosyl acceptor and isolating and/or purifying 2-O-glyceryl-?-D-glucopyranoside.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: June 16, 2020
    Assignee: TECHNISCHE UNIVERSITÄT GRAZ
    Inventors: Christiane Luley, Thornthan Sawangwan, Bernd Nidetzky, Mario Müller
  • Patent number: 10603300
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such a
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: March 31, 2020
    Inventors: Saskia Kley, Dania Birte Reiche
  • Patent number: 10568897
    Abstract: A composition for use in prevention, inhibition and/or treatment of coccidiosis in an animal is disclosed. The composition comprises an effective amount of Bidens pilosa, an active constituent thereof, or an active compound isolated therefrom. In another aspect, a composition for use in enhancing growth in an animal is disclosed. The composition comprising an animal feed and an effective amount of Bidens pilosa, or an isolated active constituent comprising a polyacetylenic compound.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: February 25, 2020
    Assignee: ACADEMIA SINICA
    Inventors: Wen-Chin Yang, Lee-Tian Chang
  • Patent number: 10568352
    Abstract: The disclosure provides nutritional compositions including a blend of amino acids and polyphenols. These nutritional compositions find use, for example, in treating and preventing EMS and laminitis in equines, as well as generally promoting animal health.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 25, 2020
    Assignee: Wiser Concepts, LLC
    Inventor: Delia Nash
  • Patent number: 10561678
    Abstract: The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 18, 2020
    Assignee: Indus Biotech Private Limited
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman
  • Patent number: 10555960
    Abstract: Methods of using and pharmaceutical compositions comprising (2R,3S,4R,5R,6S)-5-amino-6-(((1R,2S,3S,4R,6S)-4,6-diamino-3-(((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2- yl)oxy)-2-hydroxycyclohexyl)oxy)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol are disclosed, including methods of treating or preventing a nonsense mutation mediated disease associated with premature translation termination or a premature stop codon resulting from a germline or somatic nonsense mutation.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: February 11, 2020
    Assignee: PTC Therapeutics, Inc.
    Inventor: Ramil Y. Baiazitov
  • Patent number: 10538794
    Abstract: This disclosure relates to libraries of oligosaccharides comprising multiple individual oligosaccharides derived from cells that contain a tag or detectable marker. In certain embodiments, the tag or detectable marker is an oxygen linked to the oligosaccharides through the first carbon of a sugar ring. In certain embodiments, the disclosure relates to methods of generating the libraries of oligosaccharides using saccharides, e.g., monosaccharides, or a disaccharide, in which hydroxyl groups are chemically acetylated.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: January 21, 2020
    Assignee: Emory University
    Inventors: Tongzhong Ju, Richard Cummings, Matthew Kudelka
  • Patent number: 10525162
    Abstract: The present invention provides a biocompatible hydrogel composition comprising glycolipids and silk fibroin (SF) wherein glycolipid is preferably sophorolipids (SL). The said composition is useful in preparation of 3D scaffold for use in tissue engineering, and in the biomedical field. The present invention also provides a process for preparing such a composition and a process for acceleration of gelation time of silk fibroin (SF) in the presence of sophorolipid.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: January 7, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Parul Dubey, Philem Pushparani Devi, Anuya Amol Nisal, Asmita Ashutosh Prabhune
  • Patent number: 10512641
    Abstract: Described herein are methods for treating cancer in a subject in need thereof by administering chloroquine, or a salt or prodrug thereof, optionally with another agent that promotes Par-4 production to induce prostate apoptosis response-4 (Par-4) production by host cells, particularly non-cancerous host cells, to promote apoptosis in cancer cells, including androgen insensitive prostate cancer cells.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: December 24, 2019
    Assignee: University of Kentucky Research Foundation
    Inventor: Vivek M. Rangnekar
  • Patent number: 10493013
    Abstract: The present invention provides an external-use liquid skin-conditioning composition that not only reduces the sticky and friction sensations caused by the inclusion of tranexamic acid, but also has a rich body without feeling slimy and softens the skin after use. The composition comprises (A) 0.5 to 5 mass % of at least one item selected from a group consisting of tranexamic acid and derivatives thereof and (B) 0.005 to 1.5 mass % of carboxymethylcellulose, has a viscosity of no greater than 500 mPa s at 30° C., and is transparent or semitransparent with an L value between 50 and 100 inclusive. Preferably the composition contains only carboxymethylcellulose as a thickener.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: December 3, 2019
    Assignee: SHISEIDO COMPANY, LTD.
    Inventors: Chihiro Yasuda, Kazunobu Suzuki
  • Patent number: 10493087
    Abstract: Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: December 3, 2019
    Assignee: The United States of America, as represented by National Institute of Health
    Inventors: Marjan Huizing, May C. Malicdan, Nuria Carrillo
  • Patent number: 10463891
    Abstract: The present invention relates to extracts of Isochrysis sp., preferably Tahitian Isochrysis, its cosmetic, dermatological and/or therapeutic uses and compositions and cosmetic, dermatological or therapeutic products comprising such an extract of Isochrysis sp., preferably Tahitian Isochrysis.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: November 5, 2019
    Assignee: Symrise AG
    Inventors: Martina Herrmann, Holger Joppe, Paolo Pertile, Lorenzo Zanella
  • Patent number: 10449224
    Abstract: This invention relates to methods and compositions for treating pathological lung conditions using whole-grain flaxseed or flaxseed lignans (isolated in form of the lignan precursor Secoisolariciresinol diglucoside (SDG) directly from whole-grain flaxseed or chemically synthesized directly into the mammalian, readily metabolizable forms, Enterodiol (ED) or Enterolactone (EL). Such pathological condition result from oxidative lung injury such as ischemia-reperfusion injury (related to lung transplantation), radiation fibrosis and cancer. Specifically, the invention is directed to the use of flaxseed lignans in the treatment of acute and chronic lung injury as well as cancer.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: October 22, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Melpo Christofidou-Solomidou
  • Patent number: 10435692
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: October 8, 2019
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 10383847
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutically active agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: August 20, 2019
    Inventors: Dennis M. Brown, Ian Nisbet
  • Patent number: 10368569
    Abstract: The present invention relates to a natural sweetening composition comprising Luo Han Guo concentrate in an amount of 0.1 to 95% by weight and use in beverage, food, pharmaceutical, oral, dietetic, veterinary or tobacco products thereof.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: August 6, 2019
    Assignee: MONTERO GIDA SANAYI VE TICARET A.S.
    Inventors: Ahmet Toksöz, Zafer Toksöz, Onur Mutlu, Ali Türkyilmaz, Gülay Yelken, Merve Zan
  • Patent number: 10301344
    Abstract: Provided are an L-proline complex of a sodium-glucose cotransporter 2 inhibitor, and a monohydrate and a crystal of the L-proline complex. Specifically, provided are 1,6-dehydrated-1-C{4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl}-5-C-(hydroxymethyl)-?-L-idopyranose L-proline (a compound of formula (I)), a monohydrate and a type A crystal thereof, and a preparation method therefor. The obtained type A crystal of the compound of formula (I) has good chemical stability and crystal stability, and the crystallization solvent used has low toxicity and low residue, so the type A crystal can be better used in clinical treatment.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: May 28, 2019
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Piaoyang Sun, Guaili Wu, Changshan Guo, Yun Lu, Yuxia Wu, Lingjia Shen
  • Patent number: 10293013
    Abstract: The present invention provides a method of obtaining Psidium guajava leaf extract standardized to phytochemicals. The extract obtained is highly soluble in water, and contains standardized phytochemicals such as, guijavarin specifically saponins and polyphenols, which may be used in food and beverage products. The method involves the specific method of filtration to obtain highly purified form of phytochemical. The extract obtained is subjected to bio-activity guided fractionation to isolate different compounds to obtain phytochemical enriched fraction followed by purification and isolation of the single phytochemical from the enriched bioactive fraction. The phytochemical is identified as guijaverin, which also exhibits anti-diabetic activity. The Psidium guajava leaf extract is useful in food and beverage industries and is used in different formulations such as chocolates, capsules, and aqua based supplement drinks.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: May 21, 2019
    Inventors: Venkatachalam Hariharan, Pradeepkumar Siddavvanahalli Virupakshappa, Kanchana Hariharan, Paranjothi Kanni, Dipshikha Chakravortty
  • Patent number: 10206860
    Abstract: Biguanide-preserved precipitated calcium carbonate oral care compositions and methods of manufacture thereof are disclosed.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 19, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Nilza Shimohirao, Odete Tieko Yamane, Joao Abel Correia, Katrin Costa, Enzo Utima, Andre S. David
  • Patent number: 10208051
    Abstract: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: February 19, 2019
    Assignee: Duquesne University of the Holy Ghost
    Inventor: Aleem Gangjee
  • Patent number: 10174132
    Abstract: The invention provides an efficient modular chemical synthesis for heparan sulfate oligosaccharides based on orthogonal protection strategies. Modular disaccharide building blocks, themselves the product of a novel combinatorial synthesis, are combined in numerous ways to produce a range of oligosaccharides.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: January 8, 2019
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Geert-Jan Boons, Andre Venot, Sailaja Arungundram, Kanar al-Mafraji
  • Patent number: 10080752
    Abstract: The present invention provides methods for treating tumors of the brain by administering the compounds of the Formula A and particularly N-(3,4-dichloro-2-fluorophenyl)-7-({[(3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment. In the methods of the invention, the compounds disclosed herein were surprisingly found to cross the blood brain barrier. The method of the present invention further relates to the treatment of cancers of any type potentially responding to EGFR, HER2, VEGFR2, or Src family kinase inhibitors and that are found in the brain.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 25, 2018
    Assignee: KADMON CORPORATION, LLC
    Inventor: Samuel Waksal
  • Patent number: 10077444
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: September 18, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kevin Fitzgerald, Alfica Sehgal, Brian Bettencourt, Gregory Hinkle
  • Patent number: 10065982
    Abstract: The present invention provides a high-purity acid-form sophorolipid (SL)-containing composition characterized by substantially not containing acetic acid. The high-purity acid-form SL-containing composition can be produced, for example, by the following method: (i) adjusting the pH of a partially purified acid-form SL-containing composition to an acidic range; and (ii-a) subjecting an acidified partially purified acid-form SL-containing composition obtained in step (i) to chromatography to acquire a fraction containing an acid-form SL, or (ii-b) leaving the acidified partially purified acid-form SL-containing composition obtained in step (i) to stand under a low-temperature condition to acquire a resulting gelled object.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: September 4, 2018
    Assignee: Saraya Co., Ltd.
    Inventors: Yoshihiko Hirata, Mizuyuki Ryu, Hitoshi Ito, Michiaki Araki
  • Patent number: 10016358
    Abstract: The present invention relates to a vaginal suppository comprising an inert vehicle and lactic acid or a salt thereof for the treatment and/or prophylaxis of disorders in the urogenital tract. It also relates to the use of such a suppository for the production of a medicament for the treatment and/or prophylaxis of disorders in the urogenital tract as well as to a method for the treatment and/or prophylaxis of disorders in the urogenital tract.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: July 10, 2018
    Assignee: ROLF KULLGREN AB
    Inventor: Bjorn Andersch
  • Patent number: 10011628
    Abstract: Disclosed is tri- or tetravalent sialic acid derivatives comprising a core moiety to which 3 or 4 sialic acid residues are connected via a linker. Such derivatives inhibit the binding of adenovirus to human cells, whereby infections, such as epidemic keratoconjunctivitis, may be treated or prevented by administration of the tri- or tetravalent sialic acid derivatives.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: July 3, 2018
    Assignee: ADENOVIR PHARMA AB
    Inventors: Niklas Arnberg, Rémi Caraballo, Mikael Elofsson
  • Patent number: 10011627
    Abstract: C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of the compounds, preparation methods thereof, pharmaceutical compositions containing the compounds, and applications thereof are described. Compounds of formula (I) are useful as therapeutic agents, and particularly as sodium-dependent glucose contransporter protein (SGLT) inhibitors.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: July 3, 2018
    Assignee: YOUNGENE THERAPEUTICS CO., LTD
    Inventors: Huijuan Zhong, Jianchun Liao, Hongping Yu, Yaochang Xu, Qing Li, Jianghua Chen, Peng Gao, Songliang Tan, Shaobao Wang
  • Patent number: 9980928
    Abstract: Hydroxy aliphatic substituted phenyl aminoalkyl ether compounds of formula (I), and compositions thereof, are useful as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or mental disorders associated with cognitive deficits.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: May 29, 2018
    Inventors: Josep R. Prous, Neus Serradell, Ramon Flores, Noemi Garcia-Delgado, Marcel-li Carbo Banus
  • Patent number: 9982259
    Abstract: This invention provides UNA oligomers for selectively inhibiting V30M TTR expression, which can be used in treating amyloidosis. The UNA oligomers can have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers being UNA monomers and nucleic acid monomers. Embodiments include pharmaceutical compositions and methods for treating or preventing TTR-related amyloidosis by administering a UNA oligomer to a subject.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: May 29, 2018
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Kiyoshi Tachikawa, Joseph E. Payne, Padmanabh Chivukula
  • Patent number: 9974819
    Abstract: Suggested are new extracts of microalgae selected from the group consisting of (i) Monodus sp. (ii) Thalassiosira sp. (iii) Chaetoceros sp. and/or (iv) Chlorococcum sp. obtainable by treating said microalgae with a solvent selected from the group consisting of C1-C4 aliphatic alcohols, ethyl acetate, water or their mixtures, removing the dissolved extracts from the residues and recovering the pure extracts from the solvent. The extracts show excellent properties particularly in modulating the metabolism of human skin and hair follicles.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: May 22, 2018
    Assignee: Cutech S.r.L.
    Inventors: Lorenzo Zanella, Paolo Pertile, Michele Massironi, Marco Massironi, Elisa Caviola
  • Patent number: 9974984
    Abstract: The present invention relates to a composition, especially a cosmetic and/or dermatological composition, containing, in a physiologically acceptable medium, a combination of at least one monosaccharide chosen from mannose, rhamnose and a mixture thereof, and of at least one antioxidant. The present invention also relates to the use of such a composition.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: May 22, 2018
    Assignee: L'OREAL
    Inventors: Julien Laboureau, Jean-Thierry Simonnet, Pascal Portes, Karine Lucet-Levannier
  • Patent number: 9974758
    Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating tumors of the central nervous system, such as glioblastoma multiforme (GBM).
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: May 22, 2018
    Assignees: Enzo Therapeutics, Inc., Virginia Commonwealth University
    Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
  • Patent number: 9951097
    Abstract: With the rise in resistance to antibiotics such as methicillin, there is a need for new drugs. The invention provides small molecules that inhibit cellular drug targets such as UPPS and FPPS by interacting with binding pockets, thereby preventing enzyme function. Compounds described herein are also active against Staphylococcus aureus (MIC90˜0.25 ?g/mL), can potently synergize with methicillin (fractional inhibitory concentration index=0.25), and are protective in a mouse infection model. The invention therefore provides numerous compounds for anti-bacterial treatments and for restoring sensitivity to drugs such as methicillin, using combination therapies.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: April 24, 2018
    Assignees: The Board of Trustees of the University of Illinois, The Regents of the University of California
    Inventors: Wei Zhu, Steffen Lindert, Yonghui Zhang, William Sinko, Kai Li, James Andrew McCammon, Eric Oldfield
  • Patent number: 9919055
    Abstract: The present disclosure relates to sugar-linker-drug conjugates, of the formula [A-B-]n-L-D, wherein A is a saccharide; B is a spacer, n is an integer selected from 1 to 3; L is a linker group and D is a drug having a chemically reactive functional group selected from the group consisting of a primary or secondary amine, hydroxyl, sulfhydryl, carboxyl, aldehyde and ketone. Pharmaceutical compositions comprising the conjugates and methods of using them are also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 20, 2018
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Sidney Hecht, Rakesh Paul, Chenhong Tang, Manikandadas Mathilakathu Madathil, Chandrabali Bhattacharya
  • Patent number: 9879041
    Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit ?-secretase.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: January 30, 2018
    Assignees: Victoria Link Limited, University of Liverpool
    Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova, Jeremy E. Turnbull
  • Patent number: 9873712
    Abstract: A method for the purification of idraparinux sodium includes: passing a solution including a crude idraparinux sodium through a column including a sodium ion exchange resin to obtain a first mixture; passing a solution including the first mixture through a gel chromatogaphy column to obtain a second mixture; and precipitating a purified idraparinux sodium from a solution including the second mixture.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: January 23, 2018
    Assignee: Amphastar Pharmaceuticals, Inc.
    Inventors: Jundong Meng, Yonggang Xu, Wencun Wang, Song Chen, Haoning Zhang
  • Patent number: 9867767
    Abstract: The invention relates to the use of glucosylglycerol or glucosylglycerol esters with a view to increasing the expression of cell protective enzymes for the protection and stabilization of human skin and/or mucous membranes. It has been demonstrated that glucosylglycerol plays an effective role in the stimulation and activation of cell protective enzymes such as superoxide dismutase. It is thus possible in this manner to protect human skin cells effectively against damaging external influences.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: January 16, 2018
    Assignee: Bitop AG
    Inventors: Julia Klein, Gerhard Stumm
  • Patent number: 9861702
    Abstract: L-Rhamnose antigen-lipid conjugates for recruitment of the immune system to sites of tumor growth for initiating an anti-tumor antigen response. Methods for introducing L-rhamnose antigen-conjugated lipids into cell membranes such that L-rhamnose antigens are displayed on the cell surface. The cells can be tumor cells and more specifically can be melanoma cells. Cells are contacted with one or more L-rhamnose antigen-lipid conjugates such that L-rhamnose antigen-lipid conjugates are inserted into the cell membrane. The cells can be contacted for example by intratumoral injection. Pharmaceutical compositions containing the L-rhamnose antigen-lipid conjugates and therapeutic methods employing the conjugates and compositions.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 9, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Laura L. Kiessling, Rachael T. C. Sheridan, Jonathan Hudon
  • Patent number: 9822089
    Abstract: The present invention relates to the field of natural pharmaceutical chemistry, and in particular, to a resveratrol dimer (7R,8R)-trans-?-viniferin (I), a preparation process therefor and a purpose thereof in lowering a blood sugar level. According to the present invention, an R type of resveratrol dimer is separated from the resveratrol dimer by using high-speed countercurrent chromatography. Pharmacodynamic tests proved that the R type of resveratrol dimer has a better effect in lowering a blood sugar level than a racemate.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: November 21, 2017
    Assignee: China Pharmaceutical University
    Inventors: Lingyi Kong, Jianguang Luo, Chao Han, Xiaobing Wang, Hao Hong
  • Patent number: 9796689
    Abstract: By either forming a triaryl acid halide or a triaryl mixed anhydride and subsequently treating with aqueous sodium azide, triaryl acyl azides are prepared in high yield using inexpensive reagents in a process in which by-products are easily removed from the triaryl acyl azide.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: October 24, 2017
    Assignee: Dow AgroSciences LLC
    Inventors: Peter Borromeo, Carl DeAmicis
  • Patent number: 9790167
    Abstract: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: October 17, 2017
    Assignees: COMPLEXA, INC., UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Bruce A. Freeman, Bruce Branchaud
  • Patent number: 9782349
    Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: October 10, 2017
    Assignee: Ipsen Biopharma Ltd.
    Inventors: Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
  • Patent number: 9776029
    Abstract: The objective of the present invention is to provide an extinguishing agent which has excellent fire-extinguishing property and which exhibits high safety to the environment and human body. The fire extinguishing agent of the present invention is characterized in comprising a biosurfactant.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: October 3, 2017
    Assignee: KANEKA CORPORATION
    Inventors: Masashi Izumida, Satohiro Yanagisawa, Yasuyoshi Ueda
  • Patent number: 9765105
    Abstract: The present disclosure relates to a macrolide compound as shown by formula I and pharmaceutically acceptable salt thereof. The compound of the present disclosure is an antibacterial agent, and can be used to treat various bacterial and protozoal infections. The present disclosure further relates to the preparation method of the compound and a pharmaceutical composition thereof.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: September 19, 2017
    Assignee: Pulike Biological Engineering, Inc.
    Inventors: Xingjin Liu, Xuke Zhang
  • Patent number: 9757544
    Abstract: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 12, 2017
    Assignee: Lutonix, Inc.
    Inventor: Lixiao Wang
  • Patent number: RE46907
    Abstract: Disclosed is a composition comprising a derivative of NDGA and at least one metabolic modulator. The composition can be in a unit dose form or kit. The composition can comprise at least two metabolic modulators. Also disclosed are methods for achieving cytotoxicity, particularly of rapidly dividing cells such as cancer, by administering a composition of the invention. In various embodiments of the invention subjects with cancer achieve prolonged survival and/or diminution in the size of their malignancies and cancer metastasis.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 26, 2018
    Assignee: The Johns Hopkins University
    Inventors: Ru Chih C. Huang, Kotohiko Kimura
  • Patent number: RE46955
    Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: July 17, 2018
    Assignee: Progen PG500 Series Pty Ltd
    Inventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond